The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

Transcatheter aortic valve implantation has been established as an alternative treatment option for patients with severe aortic stenosis presenting with prohibitively high surgical risk or ...

The two companies have entered into a strategic partnership to exclusively commercialize Braile’s Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Aortic stenosis is a serious heart valve condition characterized by narrowing and stiffening of the aortic valve, restricting blood flow from the heart to the body. This forces the heart to work ...

Edwards Lifesciences Corporation, leading global structural heart innovation company, announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...

People with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders, even after successful valve surgery. The condition is more common in women and younger patients ...

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older patients with severe aortic stenosis following transcatheter aortic-valve ...